Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Caliper Posts Decreased Revenue, Widened Losses in Q1

SAN FRANCISCO, May 7 - Caliper Technologies today reported decreased revenues for the first quarter.

 

Total revenue for the quarter ended March 31 was $7 million compared with $9.8 million in the year-ago period.

 

Last year's first quarter revenue included a $5 million licensing fee from Aclara BioSciences as part of a litigation statement, Caliper said.

 

The net loss for the quarter was $9.7 million, or $.40 per share, compared to an income of $26.4 million, or $1.03 a share, for the same period a year ago. Included in 2001 first quarter income was a $27.5 million settlement from Aclara BioSciences. Excluding that payment, net loss for the first quarter of 2001 was $1.1 million, or $.05 a share, according to the company.

R&D spending for the quarter rose to approximately $11 million from $8.8 million for the year-ago period. 

 

The company said it had $151.3 million in cash, cash equivalents, and short-term marketable securities as of March 31.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.